The RESTORE Act would direct the Department of Health and Human Services and related federal health agencies to expand research, data collection, training, and reporting on reproductive health conditions and infertility. The bill defines a broad set of “reproductive health conditions,” including endometriosis, adenomyosis, polycystic ovary syndrome, uterine fibroids, blocked fallopian tubes, hormone imbalances, thyroid conditions, and ovulation dysfunctions, and frames infertility as a symptom of underlying disease. It also promotes “restorative reproductive medicine” and fertility awareness-based methods as approaches to diagnosing and treating these conditions, while requiring periodic federal reports on the standard of care, access to training, and insurance coverage for related services.
The bill would also affect federal grant and program administration. It would make entities primarily engaged in restorative reproductive medicine eligible for certain Title X family planning grants, encourage Teen Pregnancy Prevention grants for organizations specializing in these methods, and require training on reproductive health conditions and fertility awareness-based methods through the Reproductive Health National Training Center. In addition, it would direct HHS to evaluate and modernize medical coding and reimbursement systems so that procedures, education, and care coordination related to restorative reproductive medicine are more accurately classified and paid for under Medicare, Medicaid, and other health programs.
Beyond program and reimbursement changes, the bill would expand federal research and survey efforts. It would require literature reviews and reports on infertility diagnosis and reproductive health condition care, modify the National Survey of Family Growth to include questions on these topics, and expand HHS research on causes, diagnosis, treatment, and outcomes for reproductive health conditions, including male infertility and environmental factors such as endocrine disruptors and microplastics. The bill also includes a nondiscrimination provision barring federal, state, and local entities receiving federal funds from penalizing health care providers who decline to participate in assisted reproductive technology, including IVF, on religious or moral grounds.
The overall sentiment in the available record appears supportive but limited, with the bill introduced by Republican sponsors and no recorded committee debate or votes in the provided materials. The bill’s findings emphasize unmet needs in infertility care, delayed diagnoses, and the value of restorative approaches, suggesting a policy goal of broadening treatment options and research attention. At the same time, the absence of transcripts or votes means there is no documented formal opposition in the supplied context.
Potential points of contention are likely to center on the bill’s treatment of assisted reproductive technology, especially the provider conscience protections and the emphasis on restorative reproductive medicine over IVF or other ART approaches. Critics may question whether the bill elevates a contested medical framework, whether its grant and training provisions could shift federal family-planning resources, and whether the coding and reimbursement mandates would require significant administrative changes. Supporters are likely to view it as expanding infertility research, improving diagnosis and treatment, and increasing access to care for patients with reproductive health conditions.
The bill would amend federal health policy by directing HHS, CDC, and related agencies to study, report on, and promote restorative reproductive medicine, fertility awareness-based methods, and related infertility diagnostics and treatments. It would also affect Title X eligibility, Teen Pregnancy Prevention grant access, federal training programs, medical coding standards, and Medicare/Medicaid reimbursement practices, while adding conscience protections for providers who decline participation in assisted reproductive technology. These changes would primarily influence federal agencies, federally funded health programs, reproductive health providers, and organizations serving infertility and family planning patients.
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the bill appears to have been introduced in a favorable frame focused on expanding infertility research, improving diagnosis, and supporting alternative treatment pathways. The sponsors’ findings present the measure as a response to gaps in care and delayed diagnosis. No direct opposition or amendment activity is shown in the supplied context, so the public record here reflects introduction-stage support rather than a developed bipartisan or partisan floor debate.
The main likely controversy is the bill’s relationship to assisted reproductive technology, especially IVF, because it explicitly protects providers who refuse to assist with or refer for ART on religious or moral grounds. Another likely point of dispute is whether federal programs should prioritize restorative reproductive medicine and fertility awareness-based methods, which some may view as less established or as competing with mainstream infertility care. There may also be concern about directing Title X and other federal resources toward organizations centered on this approach, and about the administrative burden of revising coding, reimbursement, and survey systems.